ABVC News and Press, ABVC BioPharma Inc. From 11/15/22

ABVC BioPharma press release ( NASDAQ: ABVC ): Q3 GAAP EPS of -$0.11 beats by $0.09 . Revenue of $0.04M (-55.6% Y/Y) beats by $0.01M . For further details see: ABVC BioPharma GAAP EPS of -$0.11 beats by $0.09, revenue of $0.04M beats by $0.01M

FREMONT, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced its financial and operating results f...

ABVC Biopharma ( NASDAQ: ABVC ) stock rose ~6% on Monday after the company said it received a notice of allowance from the U.S. Patent and Trademark Office for ABV-1504. The patent titled, 'Polygala Extract for the Treatment of Major Depressive Disorder,' outlines ...

Fremont, CA - ( NewMediaWire ) - November 07, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that on October 20, 2022, it received a Notice of Allowance fo...

Fremont, CA - ( NewMediaWire ) - November 02, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Cedars-Sinai Medical Center (CSMC, West Hollywood CA)...

ABVC BioPharma ( NASDAQ: ABVC ) on Wednesday said it had got an approval from an Australian ethics committee for the phase 2 study plan for its vitreous substitute Vitargus. The company subsequently submitted a clinical trial application to the Australian drug regulator, the T...

ABVC Biopharma ( NASDAQ: ABVC ) said on Friday that a Phase II Part 2  study testing its ADHD drug, ABV-1505, currently being conducted at five medical centers in Taiwan, had enrolled 30 subjects and eighteen of the enrolled participants had completed t...

Fremont, CA - ( NewMediaWire ) - September 22, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced enrollment progress in the Phase II Part 2 clinical study of t...

Fremont, CA - ( NewMediaWire ) - September 13, 2022 - ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced a letter to shareholders. Dear Shareholders, I would like...

New Australia Site Confirmed to Participate in the Study  Fremont, CA - ( NewMediaWire ) - September 09, 2022 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today annou...